EPITHELIAL OVARIAN CANCER
Clinical trials for EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat ovarian cancer: phase 3 trial launches
Disease control Not yet recruitingThis study tests a new drug called BL-M07D1 against standard chemotherapy in people with HER2-positive ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 404 adults aged 18-75 will be randomly assigned to receive either BL…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:14 UTC
-
New drug cocktail offers hope for Hard-to-Treat ovarian cancer
Disease control Not yet recruitingThis study tests a combination of two drugs (liposomal irinotecan and enlonstobart) in 30 women with ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease. Participants will receive th…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 26, 2026 08:06 UTC
-
New technique could spare ovarian cancer patients from major lymph node surgery
Knowledge-focused Not yet recruitingThis study looks at whether a dye-based method can safely find the first lymph nodes that might contain cancer during early-stage ovarian cancer surgery. The goal is to see if this less invasive approach works as well as removing many lymph nodes, which can cause long-term side e…
Matched conditions: EPITHELIAL OVARIAN CANCER
Phase: NA • Sponsor: Başakşehir Çam & Sakura City Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 08:08 UTC